Maintaining an achieved weight reduction is a different question from starting treatment. This trial separated those phases explicitly. Primary publication record
Study snapshot
After a 60-week open-label tirzepatide period, 378 participants were randomized to continuation, a lower-dose strategy, or placebo for 52 weeks. Continued treatment maintained more of the weight reduction than placebo, with the reduced-dose group between those strategies on the reported overall weight estimates. The protocol included rescue treatment for substantial regain. Primary publication
Our appraisal: the maintenance population has already passed a selection stage
Participants entering maintenance had remained in the preceding treatment period. Their outcomes do not automatically describe everyone who starts treatment, including those who stop early or cannot tolerate it. The transition from enrollment to randomization should therefore remain visible.
Rescue treatment introduces another analytical question. The estimate depends on how outcomes after rescue are handled. A treatment-strategy result and a hypothetical no-rescue result can answer different questions; they should not be mixed in a single percentage claim.
The baseline used for weight change is equally important. Change from original enrollment differs from change during the maintenance phase. A participant may regain weight during maintenance while still remaining below the original baseline. Both statements can be true.
The study can inform clinical discussions about maintenance strategies, but group averages do not identify the correct plan for an individual. Full review should inspect eligibility for randomization, rescue definitions, discontinuation, missing data, and adverse events. This page does not supply dose-reduction or stopping instructions.
Frequently asked questions
Was everyone randomized when first starting treatment?
No. Randomization followed a long open-label phase.
Were three maintenance strategies compared?
Yes: continuation, reduced treatment, and placebo.
Could rescue treatment occur?
Yes, under protocol-defined conditions.
Can regain coexist with weight below original baseline?
Yes. The reference points differ.
Does a group average specify an individual's maintenance plan?
No.
Why inspect the estimand?
It determines the question answered when discontinuation or rescue occurs.
What is the core evidence boundary?
The findings apply to the selected maintenance population and tested strategies, not a universal self-directed regimen.